Hartford Healthcare returned for a $50m series C round that will support the Stanford spinout in advancing potential treatments for severe liver and inflammatory bowel diseases.

US-based regenerative antibodies developer Surrozen has picked up $50m in a series C round featuring Hartford Healthcare Trust, a subsidiary of health system Hartford Healthcare. Venture capital firms Column Group and Horizons Ventures also took part in the round, as did four new investors, of which only family office Euclidian Capital was identified. Spun out…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.